modelAcetylcysteine
Extends from Pharmacolibrary.Drugs.ATC.S.S01XA08.
Information
| name: | Acetylcysteine | |
| ATC code: | S01XA08 | route: | topical |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 0.02 | L |
| clearance: | 0.01 | L/h |
| other parameters in model implementation | ||
Acetylcysteine is a mucolytic agent used to reduce the viscosity of mucus in pulmonary diseases or for the treatment of acetaminophen (paracetamol) overdose. It is used in ophthalmology (S01XA08) as a topical agent for treatment of ocular surface disorders associated with mucous abnormalities, such as dry eye syndrome. Acetylcysteine is an established drug with both oral, intravenous, and ophthalmic (eye drop) formulations.
Pharmacokinetics
Estimated pharmacokinetic parameters for ophthalmic (topical) acetylcysteine; no literature with compartmental PK models for ocular (S01XA08) administration could be identified. Systemic absorption after ocular dosing is expected to be limited.
References
Aggarwal, R, et al., & Chauhan, MK (2020). Treatment and management strategies of onychomycosis. Journal de mycologie medicale 30(2) 100949–None. DOI:10.1016/j.mycmed.2020.100949 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32234349
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)